CA-POSIFLEX
5.1.2022 18:02:06 CET | Business Wire | Press release
Posiflex is pleased to join National Retail Federation’s Big Show for 2022 and will be showcasing its latest point-of-sale solutions in booth #5919. After a two-year-long hiatus from a live NRF show, anticipation is at an all-time high, and Posiflex is excited to exhibit its full line of point-of-sale (POS) terminals, kiosks, tablets and more—along with a few surprises—optimized for retailers in search of powerful and flexible post-pandemic solutions for their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005004/en/
In addition, Posiflex will showcase a new line of POS terminals for today’s retail demands, including the versatile XT7315 , and exciting, fresh models from the new RT6000 Series: the RT6015 and RT6016 .
The XT7315 comes with a wide selection of processors that can suit virtually any point-of-sale requirement. Running on Windows 10 IoT Enterprise OS platform, the XT7315 is housed in a stylish, durable exterior and has a well-designed base that allows for optimal cable management. With its choice of processors, plus a multi-position folding base and a fanless design, the XT7315 continues the excellence of quality and performance that the line of Posiflex XT Series is well-known for.
The new RT6000 Series includes two models: the RT6015 and RT6016, both providing a selection of Intel processors geared for maximum performance and uptime. The main difference between the two models is the display size, with the RT6015 having a 15”/4:3 standard-ratio touch screen display and the RT6016 having a 15.6”/16:9 widescreen-ratio touch screen display. Running on Windows 10 IoT Enterprise and sporting the same exceptional characteristics from the RT Series family, including sleek aesthetics, durability, performance, and reliability, the Posiflex RT6000 Series is an ideal fit for Retail, Hospitality or Specialty-Service establishments.
“With rigorous HALT/HASS testing and total in-house manufacturing that all our products experience, our new XT7315 and RT6000 terminals extend the Posiflex legacy of providing top-notch point-of-sale hardware for today’s challenging atmosphere and customers’ demands,” says Doyle Ledford, VP of Sales & Marketing for Posiflex. “We look forward to introducing these exceptional products along with the rest of our latest solutions at NRF 2022.”
About Posiflex
Since 1984, Posiflex has designed and manufactured award-winning POS terminals and peripherals. Posiflex has since grown exponentially to provide not only full-service POS stations, but also versatile self-service kiosks, state-of-the-art mobile tablets, and scalable embedded PC solutions. Renowned worldwide in the retail and hospitality industries, Posiflex is a proven leader in POS hardware for Windows and Android OS. More than 30 patents and numerous awards have been won for product innovation, design, and reliability. https://www.posiflexusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom